Johnson & Johnson (JNJ)vsLegend Biotech Corp (LEGN)
JNJ
Johnson & Johnson
$269.21
+0.01%
HEALTHCARE · Cap: $640.02B
LEGN
Legend Biotech Corp
$18.64
+0.59%
HEALTHCARE · Cap: $3.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 7602% more annual revenue ($97.93B vs $1.27B). JNJ leads profitability with a 21.5% profit margin vs -7.2%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LEGN
Hold42
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Revenue surging 51.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Weak financial health signals
ROE of -25.9% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : LEGN
The strongest argument for LEGN centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 51.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : LEGN
The primary concerns for LEGN are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LEGN is a hypergrowth play — different risk/reward profiles.
LEGN carries more volatility with a beta of 0.40 — expect wider price swings.
LEGN is growing revenue faster at 51.9% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 42/100), backed by strong 21.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Legend Biotech Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?